Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ5 | P48544 | 3/20 | 0.46 |
| ▸ | KCNJ3 | P48549 | 3/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 14/20 | 0.44 |
| ▸ | SLC43A1 | O75387 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15492800 | 1.00 | KCNJ5 (0.46) | KCNJ5KCNJ3ABCB1SLC43A1 | |
| SCHEMBL29569931 | 0.97 | KCNJ5 (0.43) | KCNJ5KCNJ3ABCB1SLC43A1 | |
| SCHEMBL15492824 | 0.94 | KCNJ5 (0.41) | KCNJ5KCNJ3ABCB1SLC43A1 | |
| SCHEMBL15491010 | 0.94 | KCNJ5 (0.41) | KCNJ5KCNJ3ABCB1SLC43A1 | |
| SCHEMBL15491012 | 0.86 | KCNJ5 (0.36) | KCNJ5KCNJ3ABCB1 | |
| SCHEMBL15492799 | 0.86 | KCNJ5 (0.36) | KCNJ5KCNJ3ABCB1 | |
| SCHEMBL15491008 | 0.81 | KCNJ5 (0.37) | KCNJ5KCNJ3ABCB1 | |
| SCHEMBL15492801 | 0.81 | KCNJ5 (0.37) | KCNJ5KCNJ3ABCB1 | |
| Kansuinin F SCHEMBL15977093 | 0.63 | ABCB1 (0.67) | KCNJ5KCNJ3ABCB1 | |
| Euphomelliferene A SCHEMBL29361080 | 0.63 | KCNJ5 (0.89) | KCNJ5KCNJ3ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846768-B2 | Use of compounds isolated from Euphorbia neriifolia for treating cancer and/or thrombocytopenia | MACKAY MEMORIAL HOSPITAL (TW) | 2014-09-30 | — | — | US | disclosed |
| US-20140056995-A1 | USE OF COMPOUNDS ISOLATED FROM EUPHORBIA NERIIFOLIA FOR TREATING CANCER AND/OR THROMBOCYTOPENIA | MACKAY MEMORIAL HOSPITAL (TW) | 2014-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140056995-A1 | USE OF COMPOUNDS ISOLATED FROM EUPHORBIA NERIIFOLIA FOR TREATING CANCER AND/OR THROMBOCYTOPENIA | PPIP5K2, XPOT, ING2 | KCNJ5 3662/4885KCNJ3 3775/4885ABCB1 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.